Academic Journal
Multimodal anti-Helicobacter pylori effects of Lactobacillus casei HY001: Evidence from in vitro and in vivo studies.
| Τίτλος: | Multimodal anti-Helicobacter pylori effects of Lactobacillus casei HY001: Evidence from in vitro and in vivo studies. |
|---|---|
| Συγγραφείς: | Lv Z; Harbin Pharmaceutical Group Bioengineering Co., LTD., Harbin, China., Yu J; Harbin Pharmaceutical Group Bioengineering Co., LTD., Harbin, China., Zhang X; Harbin Pharmaceutical Group Bioengineering Co., LTD., Harbin, China., Zhang L; Harbin Pharmaceutical Group Bioengineering Co., LTD., Harbin, China., Zhang C; Harbin Pharmaceutical Group Bioengineering Co., LTD., Harbin, China., Liu X; Harbin Pharmaceutical Group Bioengineering Co., LTD., Harbin, China., Chang Y; Harbin Pharmaceutical Group Bioengineering Co., LTD., Harbin, China., Yin H; Harbin Pharmaceutical Group Bioengineering Co., LTD., Harbin, China., Wang W; Harbin Pharmaceutical Group Bioengineering Co., LTD., Harbin, China., Zhao H; Harbin Pharmaceutical Group Bioengineering Co., LTD., Harbin, China., Li H; Harbin Pharmaceutical Group Bioengineering Co., LTD., Harbin, China. |
| Πηγή: | PloS one [PLoS One] 2026 May 14; Vol. 21 (5), pp. e0349099. Date of Electronic Publication: 2026 May 14 (Print Publication: 2026). |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: San Francisco, CA : Public Library of Science |
| Ιατρικοί όροι (MeSH): | Lacticaseibacillus casei*/physiology , Helicobacter pylori*/physiology , Helicobacter Infections*/microbiology , Helicobacter Infections*/therapy , Probiotics*/pharmacology , Probiotics*/therapeutic use, Gastric Mucosa/microbiology ; Gastric Mucosa/pathology ; Urease/metabolism ; RNA, Ribosomal, 16S/genetics ; NF-kappa B/metabolism ; Animals ; Humans ; Mice ; Bacterial Adhesion ; Male ; Gastrointestinal Microbiome |
| Περίληψη: | Helicobacter pylori (H. pylori) is a highly pathogenic microorganism that can cause various gastric diseases. Accumulating evidences have demonstrated probiotics' potential in combating H. pylori infections. The aim of this study was to explore the effects and underlying mechanism of Lactobacillus casei (L. casei) HY001 against the gastric inflammation and gastric microbiota alteration induced by H. pylori infection. These results indicated that L. casei HY001 significantly inhibited the growth of H. pylori SS1, decreased urease activity, and exhibited strong co-aggregation properties with H. pylori SS1 in vitro experiments. Furthermore, L. casei HY001 was found to be capable of inhibiting the adhesion of H. pylori SS1 with AGS cells. Subsequently, Experiments in animals suggested L. casei HY001 alleviated gastric inflammation by inhibiting the expression of NF-κ B and reducing pro-inflammatory mediator levels (IL-8, TNF-α, IL-1β, and IL-6). Moreover, the gastric microbiota 16S rRNA gene sequencing analysis revealed that L. casei HY001 improved the structure of the gastric microbiota by modulating the abundance of Firmicutes, Bacteroidota and Proteobacteria. Meanwhile, the relative abundances of Rothia, Clostridium-sensu-stricto-1, Alistipe and Prevotellacea-UG-001 were significantly increased. In contrast, the abundances of Helicobacter, Turicibacter, unclassified - Muribaculaceae, unclassified- Oscillospiraceae and Lachnospiraceae -NK4A136-group were significantly reduced following HY001 intervention. These researches indicated that L. casei HY001 improved H. pylori SS1 induced gastric mucosal damage in mice, regulated immune factors, enhanced the reduced diversity of gastric Lachnospiraceae microbiota caused by H. pylori infection, and restored the stability of the microbial community structure. (Copyright: © 2026 Lv et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.) |
| Competing Interests: | Huicheng Li is employed by Harbin Pharmaceutical Group Bioengineering Co., LTD. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The authors have declared that no other competing interests exist. |
| References: | Arch Microbiol. 2022 Apr 27;204(5):285. (PMID: 35478049) Microbiome. 2023 Aug 5;11(1):172. (PMID: 37542271) Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6. (PMID: 23193283) World J Gastroenterol. 2017 Mar 7;23(9):1521-1540. (PMID: 28321154) Foods. 2021 Aug 31;10(9):. (PMID: 34574158) Front Immunol. 2020 Jun 09;11:906. (PMID: 32582143) BMC Microbiol. 2023 Feb 11;23(1):39. (PMID: 36765272) Int J Mol Sci. 2023 Jul 20;24(14):. (PMID: 37511471) Nat Biotechnol. 2019 Aug;37(8):852-857. (PMID: 31341288) Front Immunol. 2016 Dec 05;7:563. (PMID: 27994593) Cell Host Microbe. 2020 Dec 9;28(6):838-852.e6. (PMID: 33113351) Medicine (Baltimore). 2016 Feb;95(8):e2562. (PMID: 26937896) Int J Food Microbiol. 2006 Oct 15;112(1):8-18. (PMID: 16875751) J Paediatr Child Health. 2021 Mar;57(3):431-439. (PMID: 33411344) J Natl Cancer Cent. 2024 Jul 23;4(4):369-381. (PMID: 39735438) Nat Rev Cancer. 2010 Jun;10(6):403-14. (PMID: 20495574) Nat Immunol. 2025 Feb;26(2):252-264. (PMID: 39762445) Lancet. 1984 Jun 16;1(8390):1311-5. (PMID: 6145023) EBioMedicine. 2018 Apr;30:317-325. (PMID: 29627390) Front Cell Infect Microbiol. 2021 Jul 20;11:709749. (PMID: 34354964) Minerva Gastroenterol Dietol. 2004 Jun;50(2):125-33. (PMID: 15722982) Minerva Med. 2021 Apr;112(2):281-287. (PMID: 32700868) Antibiotics (Basel). 2020 May 11;9(5):. (PMID: 32403331) Clin Nutr. 2022 Dec;41(12):2644-2650. (PMID: 36308983) Nat Biomed Eng. 2024 May;8(5):611-627. (PMID: 38561491) Sci Rep. 2024 Jun 7;14(1):13152. (PMID: 38849408) Clin Chem Lab Med. 2023 May 12;61(11):2010-2016. (PMID: 37171227) Nat Commun. 2024 Feb 22;15(1):1617. (PMID: 38388542) Front Nutr. 2022 Aug 24;9:972569. (PMID: 36091249) Ther Adv Gastroenterol. 2013 Jan;6(1):39-51. (PMID: 23320049) Antibiotics (Basel). 2024 Jun 24;13(7):. (PMID: 39061266) Gut Microbes. 2019;10(3):367-381. (PMID: 30359203) Carcinogenesis. 2022 Mar 24;43(2):126-139. (PMID: 34919670) Bioact Mater. 2025 Aug 06;53:801-818. (PMID: 40809511) Gastroenterol Res Pract. 2016;2016:7490452. (PMID: 27478434) Probiotics Antimicrob Proteins. 2023 Jun;15(3):443-450. (PMID: 34599740) Appl Environ Microbiol. 2004 Jan;70(1):518-26. (PMID: 14711683) Am J Rhinol Allergy. 2022 Jul;36(4):440-450. (PMID: 35099301) Future Microbiol. 2017 Feb;12:157-170. (PMID: 28139139) Int J Mol Sci. 2020 Feb 08;21(3):. (PMID: 32046317) Cell Host Microbe. 2024 Sep 11;32(9):1502-1518.e9. (PMID: 39197456) ACS Nano. 2023 Aug 22;17(16):16174-16191. (PMID: 37535897) Appl Microbiol Biotechnol. 2016 Apr;100(7):2939-51. (PMID: 26860942) Biomed J. 2016 Feb;39(1):14-23. (PMID: 27105595) Front Immunol. 2016 Dec 23;7:633. (PMID: 28066442) Int J Mol Sci. 2024 May 28;25(11):. (PMID: 38892046) Probiotics Antimicrob Proteins. 2015 Jun;7(2):91-100. (PMID: 25481036) World J Gastroenterol. 2015 Mar 14;21(10):2883-95. (PMID: 25780285) ACS Nano. 2024 Mar 5;18(9):7046-7063. (PMID: 38381372) Helicobacter. 2019 Sep;24 Suppl 1:e12640. (PMID: 31486235) Helicobacter. 2022 Apr;27(2):e12872. (PMID: 34997989) Curr Top Microbiol Immunol. 2023;444:53-81. (PMID: 38231215) Nutrients. 2023 Jan 27;15(3):. (PMID: 36771350) Infection. 2024 Apr;52(2):289-300. (PMID: 37917397) Anim Nutr. 2022 Aug 17;11:322-333. (PMID: 36329683) Nature. 2013 Dec 19;504(7480):446-50. (PMID: 24226770) Gastroenterology. 2015 Jun;148(7):1392-404.e21. (PMID: 25725293) Viruses. 2023 Feb 28;15(3):. (PMID: 36992360) Infect Genet Evol. 2021 Sep;93:104877. (PMID: 33905886) |
| Substance Nomenclature: | EC 3.5.1.5 (Urease) 0 (RNA, Ribosomal, 16S) 0 (NF-kappa B) |
| Entry Date(s): | Date Created: 20260514 Date Completed: 20260716 Latest Revision: 20260813 |
| Update Code: | 20260813 |
| PubMed Central ID: | PMC13175479 |
| DOI: | 10.1371/journal.pone.0349099 |
| PMID: | 42133678 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!